collection
https://read.qxmd.com/read/26176375/management-of-non-st-elevation-acute-coronary-syndrome-a-guideline-from-the-aha-and-acc
#21
JOURNAL ARTICLE
Lisa Hauk
No abstract text is available yet for this article.
July 15, 2015: American Family Physician
https://read.qxmd.com/read/26169307/current-treatment-of-dyslipidemia-evolving-roles-of-non-statin-and-newer-drugs
#22
REVIEW
Richard Kones, Umme Rumana
Since their introduction, statin (HMG-CoA reductase inhibitor) drugs have advanced the practice of cardiology to unparalleled levels. Even so, coronary heart disease (CHD) still remains the leading cause of death in developed countries, and is predicted to soon dominate the causes of global mortality and disability as well. The currently available non-statin drugs have had limited success in reversing the burden of heart disease, but new information suggests they have roles in sizeable subpopulations of those affected...
July 2015: Drugs
https://read.qxmd.com/read/26152849/experts-recommendations-for-the-management-of-adult-patients-with-cardiogenic-shock
#23
JOURNAL ARTICLE
Bruno Levy, Olivier Bastien, Bendjelid Karim, Alain Cariou, Tahar Chouihed, Alain Combes, Alexandre Mebazaa, Bruno Megarbane, Patrick Plaisance, Alexandre Ouattara, Christian Spaulding, Jean-Louis Teboul, Fabrice Vanhuyse, Thierry Boulain, Kaldoun Kuteifan
Unlike for septic shock, there are no specific international recommendations regarding the management of cardiogenic shock (CS) in critically ill patients. We present herein recommendations for the management of cardiogenic shock in adults, developed with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system by an expert group of the French-Language Society of Intensive Care (Société de Réanimation de Langue Française (SRLF)), with the participation the French Society of Anesthesia and Intensive Care (SFAR), the French Cardiology Society (SFC), the French Emergency Medicine Society (SFMU), and the French Society of Thoracic and Cardiovascular Surgery (SFCTCV)...
December 2015: Annals of Intensive Care
https://read.qxmd.com/read/26149627/atrial-flutter-and-thromboembolic-risk-a-systematic-review
#24
REVIEW
Henrik Vadmann, Peter Brønnum Nielsen, Søren Pihlkjær Hjortshøj, Sam Riahi, Lars Hvilsted Rasmussen, Gregory Y H Lip, Torben Bjerregaard Larsen
Atrial flutter confers a thromboembolic risk, but contrary to atrial fibrillation the relationship has only been addressed in few studies. This study performs an up to date systematic review of the literature to investigate the association between atrial flutter and thromboembolic events. Articles were found by MEDLINE, EMBASE search and a manual search of references list in included articles. International guidelines, meta-analyses, reviews, case reports, studies reporting thromboembolic events in relation to ablation, or cardioversion procedures, echocardiography, and observational studies were found eligible in this review...
September 2015: Heart
https://read.qxmd.com/read/25748771/diagnosis-and-management-of-acute-coronary-syndrome-an-evidence-based-update
#25
REVIEW
Jennifer N Smith, Jenna M Negrelli, Megha B Manek, Emily M Hawes, Anthony J Viera
Acute coronary syndrome (ACS) describes the range of myocardial ischemic states that includes unstable angina, non-ST elevated myocardial infarction (MI), or ST-elevated MI. ACS is associated with substantial morbidity and mortality and places a large financial burden on the health care system. The diagnosis of ACS begins with a thorough clinical assessment of a patient's presenting symptoms, electrocardiogram, and cardiac troponin levels as well as a review of past medical history. Early risk stratification can assist clinicians in determining whether an early invasive management strategy or an initial conservative strategy should be pursued and can help determine appropriate pharmacologic therapies...
March 2015: Journal of the American Board of Family Medicine: JABFM
https://read.qxmd.com/read/25517707/clinical-practice-acute-pericarditis
#26
REVIEW
Martin M LeWinter
No abstract text is available yet for this article.
December 18, 2014: New England Journal of Medicine
https://read.qxmd.com/read/25515604/the-christmas-tree-sign-a-diagnostic-tool-for-ecg-connoisseurs
#27
JOURNAL ARTICLE
C M Plymen, G S Carr-White, S Kapetanakis
No abstract text is available yet for this article.
December 16, 2014: BMJ: British Medical Journal
https://read.qxmd.com/read/25423908/early-management-of-patients-with-acute-heart-failure-state-of-the-art-and-future-directions-a-consensus-document-from-the-saem-hfsa-acute-heart-failure-working-group
#28
REVIEW
Sean P Collins, Alan B Storrow, Phillip D Levy, Nancy Albert, Javed Butler, Justin A Ezekowitz, G Michael Felker, Gregory J Fermann, Gregg C Fonarow, Michael M Givertz, Brian Hiestand, Judd E Hollander, David E Lanfear, Peter S Pang, W Frank Peacock, Douglas B Sawyer, John R Teerlink, Daniel J Lenihan
Heart failure (HF) afflicts nearly 6 million Americans, resulting in 1 million emergency department (ED) visits and over 1 million annual hospital discharges. The majority of inpatient admissions originate in the ED; thus, it is crucial that emergency physicians and other providers involved in early management understand the latest developments in diagnostic testing, therapeutics, and alternatives to hospitalization. This article discusses contemporary ED management as well as the necessary next steps for ED-based acute HF research...
January 2015: Academic Emergency Medicine
https://read.qxmd.com/read/25420051/endothelial-dysfunction-and-coronary-artery-disease-a-state-of-the-art-review
#29
REVIEW
Murugapathy Veerasamy, Alan Bagnall, Dermot Neely, John Allen, Hannah Sinclair, Vijay Kunadian
Atherosclerotic coronary artery disease (CAD) is a major cause of morbidity and mortality in the developed world. Endothelial dysfunction plays an important role in the development of atherosclerosis and predicts cardiovascular (CV) outcomes independent of conventional CV risk factors. In recent years, there have been tremendous improvements in the pharmacological prevention and management of CAD. In this review, the pathophysiology of endothelial dysfunction in relation to CAD is discussed and various techniques of invasive and noninvasive assessments of peripheral and coronary endothelial function described...
May 2015: Cardiology in Review
https://read.qxmd.com/read/25419564/association-of-loop-diuretic-use-with-higher-parathyroid-hormone-levels-in-patients-with-normal-renal-function
#30
JOURNAL ARTICLE
Kristin M Corapi, Gearoid M McMahon, Julia B Wenger, Julian L Seifter, Ishir Bhan
No abstract text is available yet for this article.
January 2015: JAMA Internal Medicine
https://read.qxmd.com/read/25399658/twelve-or-30-months-of-dual-antiplatelet-therapy-after-drug-eluting-stents
#31
RANDOMIZED CONTROLLED TRIAL
Laura Mauri, Dean J Kereiakes, Robert W Yeh, Priscilla Driscoll-Shempp, Donald E Cutlip, P Gabriel Steg, Sharon-Lise T Normand, Eugene Braunwald, Stephen D Wiviott, David J Cohen, David R Holmes, Mitchell W Krucoff, James Hermiller, Harold L Dauerman, Daniel I Simon, David E Kandzari, Kirk N Garratt, David P Lee, Thomas K Pow, Peter Ver Lee, Michael J Rinaldi, Joseph M Massaro
BACKGROUND: Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain. METHODS: Patients were enrolled after they had undergone a coronary stent procedure in which a drug-eluting stent was placed. After 12 months of treatment with a thienopyridine drug (clopidogrel or prasugrel) and aspirin, patients were randomly assigned to continue receiving thienopyridine treatment or to receive placebo for another 18 months; all patients continued receiving aspirin...
December 4, 2014: New England Journal of Medicine
https://read.qxmd.com/read/25249586/2014-aha-acc-guideline-for-the-management-of-patients-with-non-st-elevation-acute-coronary-syndromes-executive-summary-a-report-of-the-american-college-of-cardiology-american-heart-association-task-force-on-practice-guidelines
#32
JOURNAL ARTICLE
Ezra A Amsterdam, Nanette K Wenger, Ralph G Brindis, Donald E Casey, Theodore G Ganiats, David R Holmes, Allan S Jaffe, Hani Jneid, Rosemary F Kelly, Michael C Kontos, Glenn N Levine, Philip R Liebson, Debabrata Mukherjee, Eric D Peterson, Marc S Sabatine, Richard W Smalling, Susan J Zieman
No abstract text is available yet for this article.
December 23, 2014: Circulation
https://read.qxmd.com/read/24978394/systolic-blood-pressure-goals-to-reduce-cardiovascular-disease-among-older-adults
#33
JOURNAL ARTICLE
Paul Muntner, C Barrett Bowling, Daichi Shimbo
The 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) was recently published. This guideline recommended that older adults (≥60 years) without diabetes or chronic kidney disease with systolic blood pressure (SBP) ≥150 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg be initiated on antihypertensive medication with a treatment goal SBP/DBP <150/90 mm Hg. In contrast, the previous 3 JNC guidelines recommended treatment for these individuals be initiated at SBP/DBP ≥140/90 mm Hg with goal SBP/DBP <140/90 mm Hg...
August 2014: American Journal of the Medical Sciences
https://read.qxmd.com/read/24975904/diagnosis-of-heart-failure-with-preserved-ejection-fraction
#34
REVIEW
Rolf Wachter, Frank Edelmann
Heart failure with preserved ejection fraction (HFpEF) constitutes a growing health care burden worldwide. Although definitions vary somewhat among guidelines, in general the presence of typical heart failure symptoms and signs in combination with a preserved left ventricular ejection fraction (≥50%) and functional and/or structural left ventricular changes makes the diagnosis likely. This review focuses on the current understanding of diagnostic criteria, as presented in current guidelines and consensus recommendations, and on new insights from recent papers...
July 2014: Heart Failure Clinics
https://read.qxmd.com/read/24687542/%C3%AE-blockers-a-review-of-their-pharmacological-and-physiological-diversity-in-hypertension
#35
REVIEW
Toni L Ripley, Joseph J Saseen
OBJECTIVE: To review the pharmacology, pharmacokinetics, and pharmacodynamic properties of commonly used β-blockers (atenolol, carvedilol, metoprolol succinate, metoprolol tartrate, and nebivolol). DATA SOURCES: A MEDLINE literature search (1966-May 2013) was performed using the following key terms: hypertension, β-blockers, atenolol, carvedilol, metoprolol tartrate, metoprolol succinate, nebivolol, pharmacology, pharmacodynamics, pharmacokinetics, blood pressure, metabolic, lipid, central aortic pressure, diabetes, and insulin resistance...
June 2014: Annals of Pharmacotherapy
https://read.qxmd.com/read/24603191/2014-aha-acc-guideline-for-the-management-of-patients-with-valvular-heart-disease-a-report-of-the-american-college-of-cardiology-american-heart-association-task-force-on-practice-guidelines
#36
JOURNAL ARTICLE
Rick A Nishimura, Catherine M Otto, Robert O Bonow, Blase A Carabello, John P Erwin, Robert A Guyton, Patrick T O'Gara, Carlos E Ruiz, Nikolaos J Skubas, Paul Sorajja, Thoralf M Sundt, James D Thomas
No abstract text is available yet for this article.
June 10, 2014: Journal of the American College of Cardiology
https://read.qxmd.com/read/24532818/pharmacogenetics-in-the-community-pharmacy-thienopyridine-selection-post-coronary-artery-stent-placement
#37
JOURNAL ARTICLE
David F Kisor, David R Bright, Megan Conaway, Bruce A Bouts, Gregory P Gerschutz
INTRODUCTION: Although antiplatelet therapy is a mainstay of post-percutaneous coronary intervention therapy, pharmacogenetic (PGt) considerations of therapy are often ignored despite related Food and Drug Administration warnings. Pharmacists are well situated to provide PGt guidance, and the community pharmacy is one setting where PGt testing, interpretation, and recommendations can take place to ensure optimal therapeutic outcomes. CASE REPORT: A 65-year-old man who had a myocardial infarction that was treated with PCI and stent placement was determined by a community pharmacist to be a candidate for PGt testing to ensure optimal antiplatelet therapy...
August 2014: Journal of Pharmacy Practice
https://read.qxmd.com/read/24477376/improved-ticagrelor-antiplatelet-effect-on-discontinuation-of-phenytoin
#38
JOURNAL ARTICLE
Phillip Weeks, Adam Sieg, Khashayar Vahdat, Farshad Raissi, Sriram Nathan
OBJECTIVE: To report the influence of phenytoin on the antiplatelet effects of ticagrelor using a validated platelet aggregation study. CASE SUMMARY: A 71-year-old man with coronary artery disease underwent percutaneous coronary intervention to revascularize several major coronary arteries. The patient was previously on phenytoin and was initiated on ticagrelor for antiplatelet therapy following stent placement. While the patient was receiving both drugs, platelet aggregation studies revealed less platelet inhibition than would be expected in a patient not taking a concomitant inducer of ticagrelor metabolism...
May 2014: Annals of Pharmacotherapy
https://read.qxmd.com/read/24436438/risks-of-hydroxyethyl-starch-130-0-4-in-cardiac-surgery
#39
COMPARATIVE STUDY
Gary R Haynes
No abstract text is available yet for this article.
February 2014: Journal of Pharmacy Practice
https://read.qxmd.com/read/24171490/bivalirudin-started-during-emergency-transport-for-primary-pci
#40
RANDOMIZED CONTROLLED TRIAL
Philippe Gabriel Steg, Arnoud van 't Hof, Christian W Hamm, Peter Clemmensen, Frédéric Lapostolle, Pierre Coste, Jurrien Ten Berg, Pierre Van Grunsven, Gerrit Jan Eggink, Lutz Nibbe, Uwe Zeymer, Marco Campo dell' Orto, Holger Nef, Jacob Steinmetz, Louis Soulat, Kurt Huber, Efthymios N Deliargyris, Debra Bernstein, Diana Schuette, Jayne Prats, Tim Clayton, Stuart Pocock, Martial Hamon, Patrick Goldstein
BACKGROUND: Bivalirudin, as compared with heparin and glycoprotein IIb/IIIa inhibitors, has been shown to reduce rates of bleeding and death in patients undergoing primary percutaneous coronary intervention (PCI). Whether these benefits persist in contemporary practice characterized by prehospital initiation of treatment, optional use of glycoprotein IIb/IIIa inhibitors and novel P2Y12 inhibitors, and radial-artery PCI access use is unknown. METHODS: We randomly assigned 2218 patients with ST-segment elevation myocardial infarction (STEMI) who were being transported for primary PCI to receive either bivalirudin or unfractionated or low-molecular-weight heparin with optional glycoprotein IIb/IIIa inhibitors (control group)...
December 5, 2013: New England Journal of Medicine
label_collection
label_collection
5200
2
3
2015-08-17 16:50:35
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.